Recall Register

Device recall: Philips Healthcare DigitalDiagnost stationary X-ray system

Class II FDA enforcement event 74083. Recall start date: . Status in the FDA record: Terminated. Termination date: .

Reason for recall, in the words of FDA

The detector may signal that it is ready for acquisition when it actually is not, resulting in failure to properly acquire the X-ray image.

Class II, in the words of FDA

a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote

Philips Healthcare started this device recall on 10 Nov 2015. The firm address in the FDA record is in Andover, MA. FDA put the recall in Class II. FDA event 74083 has 2 product records. The first FDA enforcement report date is 15 Jun 2016. The record gives the status Terminated, with the termination date 3 May 2017.

It is important to note that most of the time recall classifications are determined after the recalling firm provides all of the information needed to determine the risk posed to public health. The classification and posting in the FDA Enforcement Report should not be seen as an expansion or change to a firm’s voluntary public warning.

FDA publishes these words. Source: FDA, Enforcement Reports, Important Note, read on . openFDA export of .

Distribution

In the words of FDA.

USA (nationwide) Distribution to the states of : ( DuraDiagnost) to the states of : OH, CA, WA and NE. (DigitalDiagnost) to the states of : AK, AZ, AL, CA, CT, CO, DE, FL, GA, HI, ID, KY, LA, MA,…

Recalling firm

Philips Healthcare, Andover, MA.

Recalling firm: The firm that the FDA record names for a recall.

FDA records how the recall started: Voluntary: Firm initiated.

Products

2 product records in the event.

FDA event 74083: product records
Recall numberProductQuantityClassStatusReport date
Z-1695-2016Philips Healthcare DigitalDiagnost stationary X-ray system160Class IITerminated15 Jun 2016
Z-1696-2016Philips Healthcare DuraDiagnost stationary X-ray system5Class IITerminated15 Jun 2016

openFDA, about the status: FDA does not update the status of a recall after the recall has been classified according to its level of hazard. As such, the status of a recall (open, completed, or terminated) will remain unchanged after published in the Enforcement Reports. Source: openFDA, Drug Recall Enforcement Reports, Disclaimer.

Enforcement report: The FDA publication that lists recalls. It has one record for each product of a recall.

Enforcement event: All the product records that have one FDA event number. This site shows one event on one page.

Class II: The middle of the three FDA recall classes.

The event in context

Device events that started in 2015
1,153
Share of these events in Class II
91%
Product records in this event
2Median of the firm: 1
Events of the firm on the register
10

Other events of the firm

Official channels

Cite this page

Recall Register. FDA enforcement event 74083. https://recallregister.com/fda/ii/74083/. Source: openFDA enforcement reports. Data through .

Sources

Source
openFDA device enforcement reports
Licence
CC0 1.0
Export date
28 Sep 2026
Newest FDA report date on the register
23 Sep 2026

FDA has one record for each product. This site puts the records with the same event number on one page. The class of the event is the highest class of its records. How the register is made. Report an error.

Questions

Where was the product distributed?
The FDA record gives this distribution: USA (nationwide) Distribution to the states of : ( DuraDiagnost) to the states of : OH, CA, WA and NE. (DigitalDiagnost) to the states of : AK, AZ, AL, CA, CT, CO, DE, FL, GA, HI, ID, KY, LA, MA,…
What quantity of product is in FDA event 74083?
The event has 2 product records. The first record gives this quantity: 160
How did the recall start?
The FDA record says: Voluntary: Firm initiated
How many device recalls of 2015 have the same class?
91% of the 1,153 device events that started in 2015 are in Class II.